Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 2/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.51 |
| ▸ | TTK | P33981 | 1/20 | 0.51 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | PAK4 | O96013 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL456871 | 0.98 | MAPT (0.51) | MAPTCASP1AURKAAURKBTTK | |
| SCHEMBL790757 | 0.80 | KMT2A (0.41) | MAPTCASP1AURKAAURKBTTK | |
| SCHEMBL789861 | 0.79 | HTT (0.39) | MAPTCASP1AURKAAURKBTTK | |
| SCHEMBL29540711 | 0.78 | MAPT (0.56) | MAPTCASP1AURKAAURKBTTK | |
| SCHEMBL8986074 | 0.78 | MAPT (0.56) | MAPTCASP1AURKAAURKBTTK | |
| SCHEMBL1882789 | 0.78 | HTT (0.46) | MAPTCASP1AURKAAURKBTTK | |
| SCHEMBL91467 | 0.77 | MAPT (0.55) | MAPTCASP1AURKAAURKBTTK | |
| SCHEMBL323430 | 0.77 | AAK1 (0.38) | MAPTCASP1AURKAAURKBTTK | |
| SCHEMBL8916 | 0.77 | PIK3CA (0.49) | MAPTKMT2AHTTPIK3CAPOLB | |
| SCHEMBL29611762 | 0.77 | PIK3CA (0.49) | MAPTKMT2AHTTPIK3CAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 392 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120887867-B | Quinoline biaryl heterocycle PI3K/HDAC double-target small molecule inhibitor and application thereof | 浙江中医药大学 | 2026-05-15 | — | — | CN | claimed |
| CN-116262758-B | 7-Methylthiazolo [5,4-d ] pyrimidine compound, preparation method and application thereof | 上海博悦生物科技有限公司 | 2025-02-28 | — | — | CN | claimed |
| CN-117964621-A | Imidazopyridine derivative and preparation method and application thereof | 河北科技大学 | 2024-05-03 | — | — | CN | claimed |
| CN-117964622-A | Novel isoxazole compound and preparation method and application thereof | 河北科技大学 | 2024-05-03 | — | — | CN | claimed |
| CN-122080012-A | Thienopyrimidine derivative, preparation method, application and pharmaceutical composition thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-120887867-B | Quinoline biaryl heterocycle PI3K/HDAC double-target small molecule inhibitor and application thereof | 浙江中医药大学 | 2026-05-15 | — | — | CN | disclosed |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12391673-B2 | LANCL ligands | NIMMUNE BIOPHARMA, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250206728-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | COILED THERAPEUTICS, INC. | 2025-06-26 | — | — | US | disclosed |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | GENENTECH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| CN-120040441-A | Compositions and methods for treating cancer | A2A制药有限公司 | 2025-05-27 | — | — | CN | disclosed |
| US-20250145589-A1 | PYRIDINE DERIVATIVE AND USE THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| US-20080293706-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2008-11-27 | — | — | US | disclosed |
| WO-2008144464-A1 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008141065-A1 | QUINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-20 | — | — | WO | disclosed |
| US-20080139557-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139557-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139557-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. | 2008-06-12 | — | — | US | disclosed |
| WO-2008033854-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033854-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139557-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, MYD88 | MAPT 4666/4885CASP1 482/4885AURKA 605/4885 |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | AZI2, TET3, OXA1L | MAPT 3374/4885CASP1 3275/4885AURKA 118/4885 |
| US-20080293706-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | PIP5K1A, PIK3CB, PIK3CG | MAPT 3879/4885CASP1 1702/4885AURKA 834/4885 |
| US-12391673-B2 | LANCL ligands | LANCL2, LANCL1, ACSL1 | MAPT 2412/4885CASP1 246/4885AURKA 3999/4885 |
| US-20250206728-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | NTPCR, PTPRC, NFATC1 | MAPT 2916/4885CASP1 3245/4885AURKA 2231/4885 |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | KRAS, NRAS, HRAS | MAPT 4847/4885CASP1 3991/4885AURKA 1709/4885 |
| US-20250145589-A1 | PYRIDINE DERIVATIVE AND USE THEREOF | KRAS, NRAS, BRAF | MAPT 3897/4885CASP1 1783/4885AURKA 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.